The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates

Tim Taber, Muhammad Mujtaba, William Goggins, Nancy Higgins, Asif Sharfuddin, Muhammad Sohail Yaqub, Dennis Mishler, Benita Book, Jeanne Chen, Andrew Lobashevsky

Research output: Contribution to journalArticle

3 Scopus citations


Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab (Rituxan; Genetech, CA, USA). A total of 31 patients were followed for up to one yr following treatment with IVIG (2 gm/kg on day 1 and day 30) and rituximab (1 g - day 15). Antibody levels were followed serially at designated time points via solid-phase single-antigen beads (SAB) method (One Lambda, Inc., Canoga Park, CA, USA). Concentration of antibodies was based on median fluorescence intensity (MFI). The majority of patients had both class I and class II antibodies (79%). Our results showed that this protocol appeared to be patient and antibody specific. The most pronounced MFI reduction in antibodies occurred within the 30- to 100-d period post-treatment. Calculated panel-reactive antibodies decreased but rebound tended to occur by 104 d after antibody MFI nadir. Because of this rebound, it can be inferred that the patients did not show a durable increase in their potential for transplantation. The search for a more effective method to immunomodulate patients continues.

Original languageEnglish (US)
JournalClinical Transplantation
Issue number4
StatePublished - Jul 2013
Externally publishedYes



  • Antibodies
  • Immunomodulation
  • Kidney
  • Sensitized
  • Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this